Kornimate/medical-research-clean huggingface dataset:
effect of the timing of cataract surgery on complications in patients with bilateral congenital cataracts

Conditions: Cataract

Summary: congenital cataract is an important treatable cause of visual handicap in childhood throughout the world. successful management of childhood cataract is dependent on individualized treatment strategies and rigorous postoperative supervision for adverse complication. in this trial, we aimed to compare the difference of postoperative outcome between surgical timing at age of 3 month and 6 month. patients enrolled into the study will be followed for two year and will have study visits at 1 day, 1 week, 1 month, 3 month, 6 month, 9 month, 12 month, 18month and 24month postoperatively.

congenital cataract is a priority of vision 2020: the right to sight, the global initiative to reduce the world's burden of avoidable blindness, because it is an important treatable cause of visual handicap in childhood throughout the world. successful management of childhood cataract is dependent on individualized treatment strategies and postoperative supervision for adverse complication is also essential. the timing of surgery of childhood cataract depends on the etiology and on the degree of visual interference. severe bilateral cataracts with significant obstruction of the visual axis must be treated and surgery is recommended as soon as possible after discovery. several previous studies claimed that ideally cataracts should be removed before 3 months of age, while the result of recent researches shows that too early intervention for cataract surgery seems aggressive and would cause serious complications, which might cause poor long-term visual outcomes. therefore, in order to control childhood blindness and severe visual impairment in china, it is of great importance to ensure that pediatric patients with cataract could have good timing of surgery, postoperative rigorous supervision, accurate optical rehabilitation and comprehensive treatment of amblyopia. in this trial, we aimed to compare the difference of postoperative outcome between surgical timing at age of 3 month and 6 month. patients enrolled into the study will be followed for two year and will have study visits at 1 day, 1 week, 1 month, 3 months, 6 months, 9 months, 12 months, 18months and 24months after cataract surgery.

Eligibility criteria:
inclusion criteria: * children diagnosis with bilateral congenital cataract for entire lens without other ocular abnormality * no more than 3 month old * have signed a consent form * can be followed exclusion criteria: * children not identified with congenital cataract * have not signed consent form * be not able to be followed
observational study of lyzme5 impact on cholesterol and body weight in man

Conditions: Overweight; Elevated Cholesterol

Summary: this observational placebo-controlled pilot study is intended to document whether or not lyzme5, an over-the-counter (otc) proprietary nutritional supplement product can positively impact, (a) weight and, (b) cholesterol levels in man.

lyzme5 is a nutritional supplement, according to the dietary supplement health and education act (dshea) of 1994. it is composed of b vitamins along with a non-essential amino acid. the individual components of this supplement are individually generally recognized as safe (have gras status). the manufacturer's objective was to create a nutritional supplement that would have the potential to positively impact body weight, and possibly one or more lipid value (i.e., total cholesterol, ldl, triglycerides)as well, in overweight individuals who may also have minimally elevated cholesterol levels. this observational clinical study will seek to recruit 100 volunteers in order to observe whether or not the weight-loss potential of lyzme5, previously observed earlier in three volunteers, can be duplicated within a larger group. the second objective is to establish whether or not lyzme5 can positively impact cholesterol levels in man.

Eligibility criteria:
inclusion criteria: * at least 21 years of age or older; * able to read, understanding, and signing a consent form; * not pregnant or breast feeding (female only); * have normal bio-markers for liver and kidney function (determined by blood test); * being at least 15 lbs over your ideal weight as defined by the body mass index \[bmi\] chart; * have a total cholesterol level of or in excess of 200 mg/dl (determined by blood test); * not using any illegal substances, including marijuana (medicinal or otherwise); * not using any "recreational drugs" * weighing less than 300 lbs exclusion criteria: * under 21 years of age; * mentally impaired; * pregnant or breast feeding; * a diabetic; * having digestion problems; * problems with kidneys, heart, or liver; * having, or have had cancer; * taking a prescription; * weight of 300 lbs or over; * total cholesterol under 200 mg/dl; * using "recreational" drugs.

Keywords: observational study
clinical implication of dac (detrusor after-contraction)

Conditions: Voiding Dysfunction

Summary: the aims of this study are * to confirm whether detrusor after-contraction (dac) is a true contraction or not with a new approach * and to understand clinical implication of dac

the definition of detrusor after-contraction (dac) is usually accepted as the increase of detrusor pressure (pdet), whether it is sudden or not, after cessation of urinary flow. the amount of increase in pdet is sometimes included in the definition of dac (14, 15, 20 cmh2o or at least two times the level of the maximal pdet during the voiding phase). however, it is clear that the lack of a well-established definition may induce much bias in the interpretation of the clinical implication of dac. the previous studies showed a wide range of prevalence.1-4 dac seemed to occur more frequently in children and the occurrence rate usually decreased with age in urodynamic studies.

Eligibility criteria:
inclusion criteria: * indications and selection of patients for conduction of urodynamic studies (uds) were followed as the recommendation of ics (international continence society). exclusion criteria: * patients with indwelling catheters, urinary tract infection and urinary stones were excluded from this study

Keywords: detrusor after-contraction urodynamic luts urinary bladder, overactive bladder dysfunction
analysis of histopathological factors predictive of lymph node involvement and management practices in pt1 colorectal cancers treated by primary endoscopic resection

Conditions: Colorectal Cancer; Colorectal Adenocarcinoma

Summary: colorectal cancers (crc) extending beyond the muscularis mucosae and invading the submucosa without extending beyond it are classified as pt1. among these, a number of lesions presenting pejorative criteria, notably histopathological, have a significant risk of lymph node invasion, and are therefore candidates for partial colectomy with lymph node dissection. tumors deemed to be at low risk of lymph node involvement can be treated by endoscopy alone. it should be noted that further surgical intervention is not without comorbid consequences, and that a significant proportion of post-surgical surgical specimens are free of cancerous lesions. the aim of this study is therefore to analyze the current histopathological criteria predictive of lymph node invasion, in order to more accurately select candidates for surgical management.


Eligibility criteria:
inclusion criteria: * consecutive patients with pt1 colorectal cancer (of adenocarcinoma subtype only) diagnosed from january the 1st, 2009 to december the 31st, 2020, with first endoscopic resection, in the area of finistère (france) exclusion criteria: * other than adenocarcinoma * other than t1 * primary surgical management * neoadjuvant treatment * refusal to data collection

Keywords: colorectal cancer pathological risk factors
an investigational scan (magnetic resonance elastography) in detecting treatment response in patients with advanced liver cancer

Conditions: Advanced Adult Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8

Summary: this trial studies how well an investigational scan (magnetic resonance elastography \[mre\]) works with standard imaging (magnetic resonance imaging \[mri\]) in detecting response to treatment in patients with liver cancer that has spread to other places in the body. diagnostic procedures, such as mre with mri, may make it easier for researchers to see if the treatment for liver cancer is working.

primary objective: i. to evaluate the ability of magnetic resonance (mr) elastography (mre) to detect changes in hepatocellular carcinoma (hcc) between baseline and after initial 6 weeks of treatment (change in mre liver tumor stiffness compared to percent non-viable/necrotic tumor). secondary objectives: i. correlate mre imaging measurements with patient survival (overall survival and time to tumor progression) over 18 months. ii. correlate mre measurements with change in tumor size and enhancement on standard of care mr imaging sequences. outline: patients undergo standard of care mri and mre over 30-90 minutes within 5 days of liver biopsy before receiving any medical treatment for hcc, at 6 weeks after medical treatment for hcc, and then every 12 weeks for up to 24 months.

Eligibility criteria:
inclusion criteria: * liver cancer. * available tumor and liver parenchyma tissue (biopsy-proven hcc). * no contraindications to mri (such implanted ferromagnetic or pump devices, metallic fragments in eye), as indicated on our departmental mri screening form. * able to undergo informed consent. * not pregnant. exclusion criteria: * contraindication to mri (including cardiac pacemaker; ferromagnetic foreign objects in the patient; metallic eye fragments; claustrophobia). * inability to comply with study and/or follow-up procedures.
hcv seek, test and rapid treatment for young pwid

Conditions: Hepatitis C; Drug Use

Summary: the purpose of this randomized study is to determine whether a community-based test and treat model of hepatitis c (hcv) care delivery will be superior to the usual care practice of referral to specialist clinics for the outcomes of sustained virologic response at 12 weeks after treatment and initiation of hcv treatment for persons who inject drugs (pwid) between ages 18 and 29 who are naïve to hcv treatment

st\&rt is a randomized open-label clinical trial in which 54 hcv infected pwid between ages 18 and 29 will be randomized to either receive the same-day treatment initiation of the fda-approved fixed dose combination of sofosbuvir 400mg and velpatasvir 100mg (sof/vel) with follow up and medical monitoring at a community site (intervention arm) or to receive referral to an hcv treatment provider's office (usual care arm).

Eligibility criteria:
inclusion criteria: * persons are eligible for study inclusion if they: (a) are hcv antibody positive, (b) are 18 to 29 years of age, (c) have injected drugs in the past 30 days, (d) are hcv treatment naïve, (e) are english speaking exclusion criteria: * persons excluded from the study will be (a) hiv coinfected persons (b) pregnant women, or women planning on becoming pregnant (c) participants with end-stage renal disease (d) participants with decompensated cirrhosis (c) participants on medications with treatment limiting interactions with sofosbuvir/velpatasvir

Keywords: pwid
effect of sufentanil on the postoperative pain

Conditions: Postoperative Pain, Acute

Summary: this study is a randomized, controlled trial. a total of 48 patients will be randomized to receive sufentanil or remifentanil during robot-assisted nephrectomy surgery.


Eligibility criteria:
inclusion criteria: * patients who undergo elective robot-assisted nephrectomy surgery * american society of anesthesiologists grade 1,2,3 * age \> 18 years old exclusion criteria: * refuse to participate to the study * allergic history of opioid * chronic pain * opioid user before surgery * mao inhibitor user * severe respiratory insufficiency
cognitive functions after covid-19

Conditions: COVID-19 Acute Respiratory Distress Syndrome; Cognitive Decline

Summary: this study was aimed to evaluate the post-infection cognitive functions of adult individuals with covid-19. 50 individuals with covid-19 and 50 healthy control groups were included in the study. cognitive functions of individuals with covid19 compared with healthy individuals.

this study was aimed to evaluate the post-infection cognitive functions of adult individuals with covid-19. fifty covid-19 patients, aged between 18-50 years, who had positive rt-pcr test in the last 60 days and later recovered, were included in the study. the study group was compared with the control group consisting of 50 healthy individuals in whom gender, age and education year has not difference significantly. participants' global cognitive skills were measured by the montreal cognitive assessment test (moca), the clock drawing test and memory functions, the öktem verbal memory processes test (ö-sbst), the attention functions by the digit span forward and digit span backwards test, the executive functions by categorical fluency, phonemic fluency, the stroop test, trail making test a and b, visuospatial skills were evaluated with the rey-osterrieth complex figure test (rocf), and behavioral symptoms were evaluated with the neuropsychiatric inventory (npi). the study group was evaluated between 21 and 60 days from the onset of the disease.

Eligibility criteria:
inclusion criteria: * having positive for the covid-19 rt-pcr test and turned negative in the last 60 days. * be 18-50 years old * 21 days have passed since the onset of the disease exclusion criteria: * having any neurological or psychiatric illness

Keywords: cognitive functions covid-19 attention executive functions memory neurophysiology
apical support during hysterectomy for pelvic organ prolapse

Conditions: Pelvic Organ Prolapse

Summary: this is a retrospective chart review using trihealth electronic privacy identification center (epic) to determine whether gynecologic surgeons at a large community hospital are already meeting the recently recommended best practice of supporting the vaginal apex.

the prevalence of pelvic organ prolapse (pop) in the united states is estimated to be between 40-50% with an anticipated increase over the next several decades. approximately 300,000 women undergo surgeries to repair pop in the united states every year. following pelvic reconstructive surgery, recurrence rates of symptomatic prolapse range between 6-30%. our understanding of pelvic anatomy and its support has been significantly improved over recent decades, with many researchers reporting on details and mechanics previously not understood. in november 2017, the american college of obstetricians and gynecologists released a new practice bulletin outlining the current standard of care for the treatment of women with pelvic organ prolapse. in this bulletin, they state that a hysterectomy alone is not adequate treatment for pelvic organ prolapse, and further that any woman having a hysterectomy for pelvic organ prolapse should undergo a concurrent apical suspension procedure as a standard of care. the purpose of this study is to determine the proportion of patients already meeting the recently recommended best practice of supporting the vaginal apex at the time of hysterectomy for pelvic organ prolapse among the population who underwent the surgery performed at a trihealth facility between october 2012 and october 2017.

Eligibility criteria:
inclusion criteria: * adults 18 years of age or older * underwent hysterectomy for pelvic organ prolapse, performed at a trihealth facility between october 2012 and october 2017 exclusion criteria: * age \< 18 years old * pelvic organ prolapse was not an indication for their surgery * surgery performed by a physician of cincinnati urogynecology associates.
plasma trial: a dose-response study of a-002 in subjects with stable coronary artery disease

Conditions: Coronary Artery Disease (CAD)

Summary: the study will be conducted at up to 80 centers worldwide and will be a double-blind randomized parallel group placebo controlled study among subjects with stable coronary artery disease (cad). subjects will be randomized to receive either placebo tablets or one of 4 orally active doses of a-002. the duration of study drug therapy will be 8 weeks.

a-002 represents a novel therapy for the treatment of atherosclerosis and coronary artery disease (cad). through the inhibition of activity a-002 may provide multifunctional activity directed against key facets of the disease process, namely a) inflammation, b) atherogenic lipid profiles and c) the atherosclerotic process. non-clinical and clinical data from recent studies have demonstrated the benefit of early and aggressive anti-inflammatory therapy to reduce cardiovascular risk. recent clinical studies have provided a strong association between levels and cardiovascular event risk. the proposed phase 2 clinical pharmacology study (study no. an-cvd-2221) will examine the effects of 4 different doses of a-002 compared with placebo, on enzyme levels and activity after 8 weeks of treatment. in addition, the effect of treatment on inflammatory markers of cardiovascular risk (c-reactive protein \[crp\]), lipid levels and lipoprotein subclasses and other soluble biomarkers (e.g., icam-1, vcam-1, tnf, mcp-1 etc) will also be assessed.

Eligibility criteria:
inclusion criteria: subjects are eligible for inclusion if they meet the following inclusion criteria: * men and women \> 18 years of age * written informed consent from the subject * stable cad * stable medical condition, will be compliant and able to comply with the requirements of the protocol exclusion criteria: * subjects must not meet any of the following exclusion criteria: * planned cabg * hospitalization for acute coronary syndrome if troponin level is \>0.1 ng/ml in the preceding 6 weeks * hospitalization for st-segment acute myocardial infarction (stemi) in the preceding 12 weeks * subjects with chronic inflammatory disease (e.g., ra), inflammatory bowel disease, recent (12 weeks) systemic or localized infection (the latter requiring clinical intervention), or major surgery * hs-crp \>15 mg/l repeated on at least 2 occasions \>24 hours apart due to non-cardiovascular systemic inflammatory conditions (e.g., rheumatoid disease) * acute or chronic heart failure as defined by the nyha classification as functional class iii or class iv

Keywords: coronary artery atherosclerosis phospholipase cad
the change in temporal muscle thickness in stroke patients

Conditions: Stroke; Sarcopenia

Summary: this study aims to evaluate the relationship between sarcopenia and functional outcomes with temporal muscle mass change.

it is well known that stroke increases the risk of developing sarcopenia . in addition, prestroke sarcopenia is associated with worse functional outcomes in patients with stroke. temporal muscle thickness (tmt) has recently been proposed as a new marker of whole-body muscle mass and function. measurement of temporal muscle mass by computed tomography (ct) and magnetic resonance imaging (mri) has been studied in the literature in recent years. all stroke patients undergo cranial ct or mri examinations at the time of admission. by evaluating the temporal muscle mass of these patients with these examinations, information about pre-stroke muscle mass and sarcopenia can be obtained. ultrasonography (usg), on the other hand, may be a more accessible, less expensive, and safer option for assessing muscle mass in the follow-up of stroke patients. this study aims to evaluate the relationship between sarcopenia and functional outcomes with temporal muscle mass change by mri/ct at admission and by usg in the chronic period.

Eligibility criteria:
inclusion criteria: * diagnosis of stroke * presence of cranial mri/ct in hospital records exclusion criteria: * medically unstable condition (presence or high risk of impaired consciousness, respiration, or circulation). * severe cognitive impairment * patients who require intensive care unit.
ghrelin and diastolic heart function

Conditions: Diabetes Mellitus, Type 2; Obesity, Abdominal; Diastolic Dysfunction

Summary: in type 2 diabetes mellitus (t2dm) and obese patients the adipose tissue could over-express cytokines, sirtuin-1 (sirt1), and micrornas (mirs) implied in the regulation of left ventricle (lv) diastolic function (lv-df). ghrelin could modulate these pathways. thus, in the current study authors will investigate ghrelin expression in t2dm obese patients after abdominal fat excision, and particularly in those with normalization of lv-df at 1 year of follow-up.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of t2dm obese patients; * t2dm obese patients under anti-diabetic full medical therapy and glycemic control. exclusion criteria: * clinical diagnosis of type 1 diabetes; * t2dm patients in poor glycemic control (hba1c values of \>7%); * chronic neurological disorders; * heart failure and coronary heart disease or depression of left ventricular ejection fraction (lvef \<55%); * severe anemia; * thyroid dysfunction; * kidney failure; * uncontrolled blood pressure (blood pressure \> 140/90 mmhg on two occasions 2 weeks apart); * inflammatory chronic disease; * neoplastic disease.
hybrid spect/ctca for the assessment of the presence and hemodynamic significance of cad in asymptomatic patients.

Conditions: Hodgkin Lymphoma Treated With Mediastinal Irradiation

Summary: mediastinal irradiation for treatment of malignancy increases the risk for coronary artery disease (cad), while diabetes mellitus or other known risk factors can be absent at the time of the first coronary event. radiation-induced atherosclerosis affects the coronary ostia and proximal coronary segments, or causes diffuse microvascular damage. younger patients and those exposed to high radiation doses (\> 35 gy) have a higher risk for developing premature cad and likely may benefit from coronary assessment. a novel hybrid imaging technique that combines spect and ctca has been shown to overcome the individual pitfalls and the diagnostic challenges of stand-alone spect and ccta, improve the lesion detectability and sensitivity in patients with balanced diffuse lesions as well as the specificity and mainly ppv of ctca. the aim of the study is to perform hybrid spect/ctca in asymptomatic patients with hl who have received radiotherapy to the mediastinum in order to allow an early diagnosis of hemodynamically significant cad that will need further therapeutic interventions.


Eligibility criteria:
inclusion criteria: * asymptomatic hl patients without evidence of disease and without prior history of cad that underwent mediastinal irradiation due to hl exclusion criteria: * known cad (these patients will be excluded from the imaging study, but will be analyzed as separate control group) * active hl or other active malignancy * chronic renal failure * pregnant/ nursing women * previous allergic reaction to iodine contrast media

Keywords: hodgkin lymphoma mediastinal irradiation coronary artery disease